An Open Lable, Phase II Exploratory Study Assessing the Efficacy of Intravenous Autologous Mesenchymal Stem Cells in Patients With Middle Cerebral Artery Infarct
Sponsor study identifier
interventional
50
1 country
1
Study Start
March 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2015
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This study aims to determine the efficacy of intravenous transplantation of autologous bone marrow-derived mesenchymal stem cells in patients with acute middle cerebral artery infarct.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 25, 2011
Actual (reported)October 28, 2011
Actual (reported)March 2012
Date type not reportedThis date has not been verified as actual or estimated.
December 2015
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Change in NIH Stroke Scale
1 year
Change in Barthel Index
1 year
Change in modified Rankin Scale
1 year
Change in size of infarct based on brain MRI stroke sequences
1 year
Change in Stroke Specific Quality of Life Scale
1 year
Change in Stroke Impact Scale
1 year
This is the control arm, which is given the best evidence-based standard treatment for the management of acute stroke
Autologous bone marrow-derived mesenchymal stem cells(BM-MSCs)
Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.
UKM Medical Centre
Kuala Lumpur, 56000, Malaysia
Norlinah Mohamed Ibrahim, MD
UKM Medical Centre
First Submitted
October 25, 2011
First Posted
October 28, 2011
Study Start
March 2012
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2015
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2016
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 1, 2015
Record last verified: 2015-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: